Development and Characterization of Metformin Nanoparticles for the Effective Treatment of Diabetes Mellitus

Pharmaceutical Sciences-Pharmaceutics for effective drug dosage

Abstract

Metformin hydrochloride is a BCS class III drug used in the management of non-insulin-dependent diabetes mellitus, as a single or in combination therapy. The aim of the present work was to develop starch nanoparticles for the delivery of Metformin hydrochloride that could reduce its dose related side effects and may prolong its release for the treatment of diabetes mellitus. Nanoparticles were prepared by the solvent evaporation technique method using starch as polymer, tween 80 as a stearic barrier and citric acid to increase the stability. The present work was aimed to develop metformin nanoparticles incorporated with starch for the effective treatment of diabetes mellitus. Framed nanoparticles were exposed to in-vitro characterization procedures for compatibility concentrates among drug and polymer, size, surface morphology, encapsulation efficacy and delivery attributes. Fourier Transform Infrared Spectroscopy results showed the compatibility nature of selected excipients for the synthesis of metformin nanoparticles. The X-Ray Diffraction Analysis (2θ values (12)) results showed developed metformin nanoparticles were non crystalline in nature. The selected developed metformin nanoparticles were in cubic phase with average particle size of 60.7± 22.54 to 118.9 ± 15.96 nm with charge ranging from 18.9 ± 0.81 to 160.7 ± 6.81mV. The encapsulation efficiency for metformin within metformin nanoparticles was about 67.84 ± 1.50 to 79.97 ± 0.9 %. The in vitro drug release studies of MN3 showed controlled drug release profile as compared to pure metformin. Further, the results of in vivo studies in terms of blood glucose profile showed significant effect for the developed metformin nanoparticles for the treatment of diabetes mellitus.